International Journal of Hematology

, Volume 91, Issue 2, pp 258–266

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group

Authors

  • Ritsuko Seki
    • Division of Hematology and Oncology, Department of MedicineKurume University School of Medicine
    • Research Center for Innovative Cancer TherapyKurume University
  • Koichi Ohshima
    • Department of PathologyKurume University School of Medicine
    • Research Center for Innovative Cancer TherapyKurume University
  • Koji Nagafuji
    • Division of Hematology and Oncology, Department of MedicineKurume University School of Medicine
  • Tomoaki Fujisaki
    • Department of Internal MedicineMatsuyama Red Cross Hospital
  • Naokuni Uike
    • Department of HematologyNational Kyushu Cancer Center
  • Fumio Kawano
    • Department of Internal MedicineNational Hospital Organization, Kumamoto Medical Center
  • Hisashi Gondo
    • Department of Internal MedicineSaga Prefectural Hospital Koseikan
  • Shigeyoshi Makino
    • Department of Internal MedicineMiyazaki Prefectural Hospital
  • Tetsuya Eto
    • Department of HematologyHamanomachi Hospital
  • Yukiyoshi Moriuchi
    • Department of HematologySasebo City General Hospital
  • Fumihiro Taguchi
    • Department of HematologyIizuka Hospital
  • Tomohiko Kamimura
    • Department of HematologyHarasanshin General Hospital
  • Hiroyuki Tsuda
    • Division of Clinical HematologyKumamoto City Hospital
  • Ryosuke Ogawa
    • Shimonoseki City Central Hospital
  • Kazuya Shimoda
    • Department of Internal Medicine, Gastroenterology and Hematology, Faculty of MedicineMiyazaki University
  • Kiyoshi Yamashita
    • Department of Internal Medicine, Gastroenterology and Hematology, Faculty of MedicineMiyazaki University
  • Keiko Suzuki
    • Department of Internal MedicineKoga General Hospital
  • Hitoshi Suzushima
    • Department of Internal MedicineNTT Nishinippon Kyushu General Hospital
  • Kunihiro Tsukazaki
    • Molecular Medicine Unit and Hematology, Atomic Bomb Disease InstituteNagasaki University Graduate School of Biomedical Sciences
  • Masakazu Higuchi
    • Department of Internal MedicineKyushu Kosei-nenkin Hospital
  • Atae Utsunomiya
    • Department of HematologyImamura Bun-in Hospital
  • Masahiro Iwahashi
    • Department of Internal MedicineSaiseikai-Hita Hospital
  • Yutaka Imamura
    • Department of HematologySt. Mary Hospital
  • Kazuo Tamura
    • Division of Medical Oncology and Hematology, Department of MedicineFukuoka University Hospital
  • Junji Suzumiya
    • Department of Internal MedicineFukuoka University Chikushi Hospital
  • Minoru Yoshida
    • Japanese Red Cross Kumamoto Health Care Center
  • Yasunobu Abe
    • Department of Medicine and Bioregulatory Science, Graduate School of Medical ScienceKyushu University
  • Tadashi Matsumoto
    • Department of HematologyImamura Hon-in Hospital
    • Division of Hematology and Oncology, Department of MedicineKurume University School of Medicine
    • Research Center for Innovative Cancer TherapyKurume University
    • Division of Hematology, Department of MedicineKurume University School of Medicine
Original Article

DOI: 10.1007/s12185-009-0475-2

Cite this article as:
Seki, R., Ohshima, K., Nagafuji, K. et al. Int J Hematol (2010) 91: 258. doi:10.1007/s12185-009-0475-2

Abstract

We performed a retrospective analysis of patients with diffuse large B cell lymphoma treated with rituximab plus CHOP (cyclophosphamide, adriamycin, vincristine and prednisone) as a first-line therapy at 22 hospitals of the Kyushu Lymphoma Study Group. During the period 1996–2005, 1,057 patients (aged 22–90 years) were analyzed. Of these, 678 were treated with CHOP, and 379 were treated with rituximab plus CHOP (R-CHOP). The complete response rate was 59.9% in the CHOP group and 67.0% in the R-CHOP group (P < 0.001). Three-year progression-free survival (PFS) and overall survival (OS) rates were significantly higher in the R-CHOP group than in the CHOP group (61.3 vs. 45.6% for PFS, P < 0.001; 68.3 vs. 54.5% for OS, P < 0.001). The International Prognostic Index was a good prognostic marker for both groups; a survival benefit of rituximab addition was found for each risk subgroup and also for both age groups (≤60 and >60 years). Among 345 patients who received localized radiation therapy, the adding rituximab to CHOP attenuated the survival difference between CHOP and R-CHOP groups (P = 0.104), compared with no radiation group (P < 0.001). Results of this large-scale, multicenter study confirm that rituximab plus CHOP provided a greater survival benefit than CHOP alone.

Keywords

DLBCL Rituximab CHOP Radiation Prognosis

Copyright information

© The Japanese Society of Hematology 2010